NCT05363280 2025-09-23
Phase 2 Safety and Efficacy Evaluation of AL8326 in ≥2nd Line SCLC
Advenchen Laboratories, LLC
Phase 2 Active not recruiting
Advenchen Laboratories, LLC
Shenzhen Salubris Pharmaceuticals Co., Ltd.
Monyan Pharmaceutical (Shanghai) Co., Ltd.
Aalborg University Hospital
Peking Union Medical College Hospital